pharmaphorum January 14, 2021
Sarah Rickwood

In this second ‘Nine for 2021‘ article, IQVIA’s Sarah Rickwood looks at four issues which will directly impact pharma in 2021: the permanent changes in customer engagement models, the implications of a geographic re-balancing towards the East, CNS as the new value growth area for the 2020s, and the new biologics environment as biosimilars accelerate.

Focus on customer engagement impact

The customer engagement story of 2020 could be summarised in three themes: trend break, agility and remote interaction. The trend break was the most immediately measurable commercial model impact. For April 2020 almost all face-to-face contact with healthcare professionals (HCPs) ceased. Preventing virus transmission, as well as “getting out of the way” of healthcare professionals pivoting to address the virus...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Healthcare System, Pharma, Pharma / Biotech, Public Health / COVID, Trends
FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
This Biotech Startup Aims To Speed Up Drug Testing On Animals
Scientists reveal new method that could reduce waste from drug manufacturing
ETH develops AI algorithm for drug discovery based on 3D protein surface
Pharma Pulse 4/26/24: 20 States Select Direct Care Workforce Enhancement Programs by HHS, Do Assigned Roles in Clinical Trials Affect Patient-Reported Outcomes? & more

Share This Article